|Mr. Remi Barbier||Founder, Chairman, President & CEO||1.11M||297.42k||1960|
|Mr. Eric J. Schoen||Chief Financial Officer||426.61k||N/A||1968|
|Mr. R. Christopher Cook||Senior VP, Company Secretary & General Counsel||457.64k||N/A||1964|
|Dr. James W. Kupiec M.D.||Chief Medical Officer||400k||N/A||1953|
|Dr. George Thornton||Senior Vice President of Technology||N/A||N/A||N/A|
|Mr. Michael Zamloot||Senior Vice President of Technical Operations||N/A||N/A||N/A|
|Dr. Michael Marsman Pharm.D.||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Lindsay H. Burns Ph.D.||Senior Vice President of Neuroscience||N/A||N/A||N/A|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.’s ISS governance QualityScore as of 28 November 2023 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 8.